Does gap-free intensity modulated chemoradiation therapy provide a greater clinical benefit than 3D conformal chemoradiation in patients with anal cancer?

Radiation Oncology

Gilles Créhange²  Sylvain Dewas³  Cédric Khoury²  Etienne Martin²  Gilles Truc²  Karine Peignaux²  Aurélie Petitfils²  Cécile Dalban¹  Philippe Maingon²  Claire Vautravers Dewas² 

[1] Department of Biostatistics, Anticancer center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France;Department of Radiation Oncology, Anticancer center Georges François Leclerc, 1 rue du Professeur Marion, Dijon, 21000, France;Departement of Radiation Oncology, Centre Oscar Lambret, Cedex 3 rue Frédéric combemale B.P, LILLE, 307 59020, France

关键词: Toxicity;    3D-CRT;    IMRT;    Chemoradiation;    Anal canal cancer;   

Others  :  1154985
DOI  :  10.1186/1748-717X-7-201

 received in 2012-08-03, accepted in 2012-11-21,  发布年份 2012

【 摘 要 】

Background

Chemoradiation is the standard treatment for anal cancer. 3D conformal radiotherapy (3D-CRT) is usually split in 2 sequences with a therapeutic break (gap) in between. Intensity-modulated radiation therapy (IMRT) makes it possible to reduce treatment time by abandoning this gap. The purpose of this study was to compare outcomes and toxicities in patients treated with either IMRT or 3D-CRT.

Methods

Between 2004 and 2011, the data of 51 patients treated with exclusive radiotherapy with or without concomitant chemotherapy for non-metastatic anal carcinoma were retrospectively analyzed. Twenty-seven patients were treated with 3D-CRT and 24 patients with IMRT, with a median dose delivered to the tumor of 59.4Gy [30.6-66.6], whatever the radiotherapy technique (p= 0.99). The median follow-up was 40 months [26.4-51.6].

Results

There was no difference between the two groups for response to treatment (p= 0.46). Two-year overall survival, locoregional relapse-free survival and colostomy-free survival rates were 88.5%, 63% and 60.3%, respectively for the IMRT group and 81%, 76.5% and 81.1% for the 3D-CRT group (all NS). Ten patients (37%) in 3D-CRT and 11 patients (45.8%) in IMRT (p= 0.524) had grade 3 acute toxicity. No grade 4 toxicity occurred.

Conclusions

Our study suggests that further investigations concerning the use of IMRT to treat cancer of the anus are warranted. IMRT makes it possible to remove the gap, but with no impact on the prognosis. Nonetheless, a longer follow-up is essential to determine whether or not IMRT has an impact on late toxicity, local control and survival compared with conventional 3D-CRT.

【 授权许可】

   
2012 Dewas et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Epidermoid anal cancer: results from the UKCCCR randomised trial of radiotherapy alone versus radiotherapy, 5-fluorouracil, and mitomycin: UKCCCR Anal Cancer Trial Working Party. UK Co-ordinating Committee on Cancer Research. Lancet 1996, 348:1049-1054.
• [2]Bartelink H, Roelofsen F, Eschwege F, Rougier P, Bosset JF, Gonzalez DG, Peiffert D, van Glabbeke M, Pierart M: Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997, 15:2040-2049.
• [3]Flam M, John M, Pajak TF, Petrelli N, Myerson R, Doggett S, Quivey J, Rotman M, Kerman H, Coia L, Murray K: Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996, 14:2527-2539.
• [4]Bosset JF, Roelofsen F, Morgan DA, Budach V, Coucke P, Jager JJ, Van der Steen-Banasik E, Triviere N, Stuben G, Puyraveau M, Mercier M: Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European Organization for Research and Treatment of Cancer. Radiotherapy and Gastrointestinal Cooperative Groups. Eur J Cancer 2003, 39:45-51.
• [5]Konski A, Garcia M Jr, John M, Krieg R, Pinover W, Myerson R, Willett C: Evaluation of planned treatment breaks during radiation therapy for anal cancer: update of RTOG 92-08. Int J Radiat Oncol Biol Phys 2008, 72:114-118.
• [6]Bazan JG, Hara W, Hsu A, Kunz PA, Ford J, Fisher GA, Welton ML, Shelton A, Kapp DS, Koong AC, et al.: Intensity-modulated radiation therapy versus conventional radiation therapy for squamous cell carcinoma of the anal canal. Cancer 2011, 117:3342-3351.
• [7]Deniaud-Alexandre E, Touboul E, Tiret E, Sezeur A, Houry S, Gallot D, Parc R, Huang R, Qu SH, Huart J, et al.: Results of definitive irradiation in a series of 305 epidermoid carcinomas of the anal canal. Int J Radiat Oncol Biol Phys 2003, 56:1259-1273.
• [8]Ben-Josef E, Moughan J, Ajani JA, Flam M, Gunderson L, Pollock J, Myerson R, Anne R, Rosenthal SA, Willett C: Impact of overall treatment time on survival and local control in patients with anal cancer: a pooled data analysis of Radiation Therapy Oncology Group trials 87-04 and 98-11. J Clin Oncol 2010, 28:5061-5066.
• [9]Constantinou EC, Daly W, Fung CY, Willett CG, Kaufman DS, DeLaney TF: Time-dose considerations in the treatment of anal cancer. Int J Radiat Oncol Biol Phys 1997, 39:651-657.
• [10]Meyer A, Meier Zu Eissen J, Karstens JH, Bremer M: Chemoradiotherapy in patients with anal cancer: impact of length of unplanned treatment interruption on outcome. Acta Oncol 2006, 45:728-735.
• [11]Menkarios C, Azria D, Laliberte B, Moscardo CL, Gourgou S, Lemanski C, Dubois JB, Ailleres N, Fenoglietto P: Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: a comparison of conventional and IMRT plans. Radiat Oncol 2007, 2:41. BioMed Central Full Text
• [12]Milano MT, Jani AB, Farrey KJ, Rash C, Heimann R, Chmura SJ: Intensity-modulated radiation therapy (IMRT) in the treatment of anal cancer: toxicity and clinical outcome. Int J Radiat Oncol Biol Phys 2005, 63:354-361.
• [13]Pepek JM, Willett CG, Wu QJ, Yoo S, Clough RW, Czito BG: Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. Int J Radiat Oncol Biol Phys 2010, 78:1413-1419.
• [14]Salama JK, Mell LK, Schomas DA, Miller RC, Devisetty K, Jani AB, Mundt AJ, Roeske JC, Liauw SL, Chmura SJ: Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience. J Clin Oncol 2007, 25:4581-4586.
• [15]Ajani JA, Winter KA, Gunderson LL, Pedersen J, Benson AB 3rd, Thomas CR Jr, Mayer RJ, Haddock MG, Rich TA, Willett C: Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: a randomized controlled trial. JAMA 2008, 299:1914-1921.
• [16]Matzinger O, Roelofsen F, Mineur L, Koswig S, Van Der Steen-Banasik EM, Van Houtte P, Haustermans K, Radosevic-Jelic L, Mueller RP, Maingon P, et al.: Mitomycin C with continuous fluorouracil or with cisplatin in combination with radiotherapy for locally advanced anal cancer (European Organisation for Research and Treatment of Cancer phase II study 22011-40014). Eur J Cancer 2009, 45:2782-2791.
• [17]Hodges JC, Das P, Eng C, Reish AG, Beddar AS, Delclos ME, Krishnan S, Crane CH: Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. Int J Radiat Oncol Biol Phys 2009, 75:791-794.
• [18]Kachnic LA, Winter KA, Myerson R, Goodyear M, Willins J, Esthappan J, Haddock M, Rotman M, Parikh P, Willett C: RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5-Fluorouracil and Mitomycin-C for reduction of acute morbidity in carcinoma of the anal canal. 51st ASTRO Annual Meeting Chicago 2009, PS5.
• [19]Kachnic LA, Winter KA, Myerson R, Goodyear M, Willins J, Esthappan J, Haddock M, Rotman M, Parikh P, Willett C: Two year outcomes of RTOG 0529: a phase II evaluation of dose-painted IMRT in combination with 5FU and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal. ASCO Annual Meeting; Chicago 2011. Abstr. 368
• [20]Kachnic LA, Tsai HK, Coen JJ, Blaszkowsky LS, Hartshorn K, Kwak EL, Willins JD, Ryan DP, Hong TS: Dose-painted Intensity-modulated Radiation Therapy for Anal Cancer: A Multi-institutional Report of Acute Toxicity and Response to Therapy. Int J Radiat Oncol Biol Phys 2012, 82:153-158.